This website is intended for healthcare professionals only and contains promotional content.

Report an adverse event here
Link Logo
United Kingdom - English

United Kingdom - English

United Kingdom | English

These country specific websites are specifically intended for healthcare professionals in listed countries only.

Europe

Deutschland - DeutschDeutschland - Deutsch España - EspañolEspaña - Español Italia - ItalianoItalia - Italiano United Kingdom - EnglishUnited Kingdom - English

NOTICE: Kyowa Kirin International has agreed a joint venture with Grünenthal GmbH for the Established Medicines portfolio. The new company, KKI NewCo (known as Grünenthal Meds), is responsible for the content on this page. For more information please click here.​

Sancuso-product-image

SANCUSO®

granisetron transdermal patch

SANCUSO transdermal patch is indicated for the prevention of nausea and vomiting associated with moderately or highly emetogenic multi-day chemotherapy in adult patients with swallowing difficulties.1

Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse Events should also be reported to Kyowa Kirin International UK NewCo Ltd, known as Grünenthal Meds on +44 (0)1896 664000, email PVUK@grunenthalmeds.com

Click here for prescribing information.

What is SANCUSO used for?

Chemotherapy has helped millions of people in their battle against cancer as it destroys cancer cells.

Unfortunately, healthy, non-cancerous cells are sometimes destroyed too, which can lead to unpleasant side effects, such as chemotherapy-induced nausea and vomiting (CINV). While some types of chemotherapy may cause nausea and vomiting, medications like SANCUSO are designed to help prevent CINV from occurring.

SANCUSO is the first and only patch for CINV control.2 

Effective control

In a recent study, nearly 80% of patients, who used SANCUSO for their CINV, achieved complete control of daily CINV symptoms throughout the course of their chemotherapy.3 Complete control is defined as:3

  • No vomiting / retching.
  • No more than mild nausea.
  • No need for rescue medication.

Convenient option

SANCUSO provides an alternative option for those on chemotherapy, in which oral anti-emetic administration is complicated by factors making swallowing difficult.1

Continuous protection

SANCUSO provides continuous protection from CINV throughout the multi-day chemotherapy regimen.4

  • Prophylaxis of CINV is more difficult in patients receiving multi-day chemotherapy regimens as both acute and delayed CINV may occur.4
  • SANCUSO delivers an average daily dose of granisetron of 3.1 mg for up to 7 days,1 thereby reducing the need for repeated oral dosing.

SANCUSO and ondanestron

SANCUSO offers potential benefits when compared to ondansetron.

A multi-centre, randomised, open-label, parallel-group, active-controlled phase IV study was conducted to evaluate the efficacy and safety of SANCUSO (n=199), with ondansetron (n=190) as the control.

  • Non-inferiority for complete response was demonstrated versus ondansetron (complete response is defined as no retching, vomiting or use of rescue medication).5
  • There was no significant difference in complete control rate, and severity and frequency of nausea and retching/vomiting between the two groups, however:
  •  Complete control rate of the SANCUSO group on Day 5 was significantly higher compared with the ondansetron group (p=0.0278).5
  • The patient’s quality of life assessment (Functional Living Index - Emesis) was significantly higher in the SANCUSO group (p=0.0449).5

Average:

  • References

    1. SANCUSO 3.1 mg/24 hours transdermal patch SPC.

    2. eMIMS. June 2021.

    3. SANCUSO European Public Assessment Report EMA/228344/2012.

    4. Boccia R et al. Support Care Cancer. 2011;19:1609-1617.

    5. Sun D-S, Korean Cancer Association Presentation 2013.

    6. Howell J et al. J Oncol Pharm Pract. 2009;15:223-31.

    KKI/UK/IM-M1/0001 November 2023